Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Pharmacologic Substance > Weight-Loss Agents

Weight-Loss Agents

Weight-Loss Agents are substances or interventions that promote the reduction of body weight.
These may include pharmacological agents, dietary supplements, or lifestyle modifications designed to facilitate weight loss.
Researchers studying weight-loss agents aim to identify the most effective and safe products and protocols to help individuals achieve their weight management goals.
By exploring cutting-edge research from publications, preprints, and patents, scientists can unlock the secrets of optimizing weight-loss agents and gain a decisive edge in their work.
PubCompare.ai offers intelligent tools to effortlessly locate and compare the latest findings, empowering researchers to unlock their full potential in the field of weight-loss agent optimization.

Most cited protocols related to «Weight-Loss Agents»

1
Behavioral and Biological Measurements of AHAB Participants
Cited 18 times
Data were derived from the University of Pittsburgh Adult Health and Behavior (AHAB) registry, which is comprised of behavioral and biological measurements obtained on non-Hispanic white and African American individuals recruited between 2001 and 2005 via mass-mail solicitation from communities of southwestern Pennsylvania, USA (principally Allegheny County) (Cf., 14 – 16). Subjects were 1046 male (49%) and female AHAB participants, aged 30–54 years. Eighty-four percent of participants were White and 16% African American. Study exclusions were a reported history of atherosclerotic cardiovascular disease, chronic kidney or liver disease, cancer treatment in the preceding year, and major neurological disorders, schizophrenia or other psychotic illness. Other exclusions included pregnancy and the use of insulin, glucocorticoid, antiarrhythmic, psychotropic, or prescription weight-loss medications. Data collection occurred over multiple laboratory sessions, and informed consent was obtained in accordance with approved protocol and guidelines of the University of Pittsburgh Institutional Review Board.
Manuck S.B., Phillips J., Gianaros P.J., Flory J.D, & Muldoon M.F. (2009). Subjective Socioeconomic Status and Presence of the Metabolic Syndrome in Midlife Community Volunteers. Psychosomatic medicine, 72(1), 35-45.
Publication 2009
Adult African American Anti-Arrhythmia Agents Atherosclerosis Biopharmaceuticals Ethics Committees, Research Glucocorticoids Hepatobiliary Disorder Hispanics Insulin Kidney Males Malignant Neoplasms Mental Disorders Nervous System Disorder Pregnancy Psychotropic Drugs Schizophrenia Weight-Loss Agents Woman
2
Multiethnic Body Composition Study
Cited 13 times
As described previously [10] , [11] , study subjects were recruited from a random sample (n = 218) of participants in the Multiethnic Cohort Study [12] who were female residents of Oahu, Hawaii, were 60–65 years of age as of September 2009, and had BMIs in the range of 18.5–40 kg/m2. All reported that both of their parents were either of Caucasian or Japanese ethnicity. Exclusion criteria included current smoking, use of selected medications (chemotherapy, insulin, or weight-loss drugs), a substantial weight change (≥ 20 pounds in the past six months) or soft or metal implants/objects in the body (n = 46). An additional 98 women were unavailable or unwilling to participate. Among the 74 remaining eligible women, we selected 60 women (30 Caucasians and 30 Japanese Americans) distributed equally across BMI categories (cutoff points at BMI 22, 25, 27.5, and 30 kg/m2) to obtain a balanced representation by ethnicity and BMI levels.
Participants underwent anthropometric measurements, a DXA scan and a fasting venous blood collection at the University of Hawaii Clinical Research Center (UH-CRC). Forty-eight of the 60 women (28 Caucasian and 20 Japanese American) also agreed to participate in an MRI scan at the University of Hawaii and Queen’s Medical Center (UH-QMC) MR Research Center. The Institutional Review Boards of UH and QMC approved the study protocol, and all participants signed an informed consent.
Lim U., Turner S.D., Franke A.A., Cooney R.V., Wilkens L.R., Ernst T., Albright C.L., Novotny R., Chang L., Kolonel L.N., Murphy S.P, & Le Marchand L. (2012). Predicting Total, Abdominal, Visceral and Hepatic Adiposity with Circulating Biomarkers in Caucasian and Japanese American Women. PLoS ONE, 7(8), e43502.
Full text: Click here
Publication 2012
BLOOD Caucasoid Races Dual-Energy X-Ray Absorptiometry Ethics Committees, Research Ethnicity Females Human Body Insulin Japanese Japanese Americans Metals MRI Scans Parent Pharmaceutical Preparations Pharmacotherapy Veins Weight-Loss Agents Woman
3
Weight Maintenance for Obese Adults
Cited 12 times
Types of studies—We included randomised controlled trials or cluster randomised controlled trials with participants randomised to a weight maintenance intervention compared with a control condition or another intervention, or both, and ≥12 months’ follow-up of weight outcomes from inception of the maintenance intervention.
Types of participants—Participants were adults (aged ≥18, no upper age limit) who had, or had had, an average BMI of ≥30 and lost ≥5% of their body weight/mass within 24 months before weight loss maintenance treatment. We excluded studies that recruited participants with established mental health conditions, including eating disorders, and conditions requiring treatment with antipsychotic drugs.
Type of interventions—Any behavioural/lifestyle, pharmacological (with European Medicines Agency approval for weight loss), food replacement/supplement, or alternative interventions, singly or in combination were included. We excluded surgical interventions.
Types of outcomes—Primary outcome was weight at 12 months from randomisation to the weight loss maintenance intervention. Weight could be reported as absolute weight change during the trial including the weight loss phase, weight change during the maintenance treatment period, or final weight values.
Types of reports—Full text reports in any language from 1946 to January 2014.
Dombrowski S.U., Knittle K., Avenell A., Araújo-Soares V, & Sniehotta F.F. (2014). Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials. The BMJ, 348, g2646.
Publication 2014
Adult Antipsychotic Agents Dietary Supplements Eating Disorders Europeans Healthy Volunteers Operative Surgical Procedures Vaginal Diaphragm Weight-Loss Agents
4
Stepped-care vs. Standard Weight Loss for Binge Eating
Cited 7 times
Sample size was based on power calculations for primary aim (Stepped-care vs BWL (Standard)) and secondary aims (within Stepped-care) based on data from RCTS for BED testing BWL, CBTgsh, and sibutramine cited above, considering clinically-meaningful effect sizes, and performing sensitivity analyses for different outcomes. A target sample of N=175 allocated in a 4:1 ratio for Stepped-care versus BWL (Standard) yielded 80–85% power for medium effect sizes (Cohen’s d=0.57) for main outcomes at two-sided alpha level of 0.05.
Analyses designed to compare treatments were all “intent-to-treat” (ITT) and were performed for all randomized patients. Baseline characteristics (demographic, psychiatric, and clinical variables) for the treatment groups were compared using chi-square analyses for categorical variables and ANOVAs for continuous measures.
The two primary treatment outcome variables were binge eating and weight loss. Binge eating was analyzed using complementary approaches (remission and frequency) and weight loss was calculated as percent weight loss from baseline. “Remission” from binge eating was defined as zero binges (OBEs) during the previous 28 days (assessed by the EDE); for “remission,” any instances of treatment dropouts or missing data, pre-treatment baseline data were carried forward (i.e., failure imputed). Secondary treatment outcomes were eating-disorder psychopathology (global EDE), depression (BDI), and physical variables (waist circumference, total cholesterol).
For analyses of continuous measures, ITT approach was followed with all available data used in mixed models analyses without imputation. All treatment outcomes (except remission) were analyzed using mixed effects models (Gueorguieva & Krystal, 2004 (link); Gueorguieva & Sanacora, 2006 (link)) with group (Stepped-care vs. BWL (Standard)) as a between-subject factor, time as a within-subject factor and the interaction between group and time. Treatment groups were compared on remission rates (yes/no) using chi-square tests at post-treatment.
To examine secondary goals, additional analyses examined whether the different treatments differed, whether the averages for the weight-loss medication conditions were superior to those for the averages for the placebo, and whether each medication condition differed from each respective control (i.e., BWL+Med vs. BWL+Pla, and CBTgsh+Med vs. CBTgsh+Pla). Lastly, because the weight-loss medication used changed during the course of the study, analyses compared subitramine, orlistat, and placebo within Stepped-care.
Variables not conforming to normality were log-transformed prior to analysis. The best-fitting variance-covariance structure (among unstructured, autoregressive, auto-regressive heterogeneous, compound symmetry, compound symmetry heterogeneous) was selected using Schwartz-Bayesian criterion. Significant main/interaction effects were explained by tests of simple effects or pairwise comparisons. Overall tests were considered significant at 0.05 level.
Grilo C.M., White M.A., Masheb R.M., Ivezaj V., Morgan P, & Gueorguieva R. (2020). Randomized Controlled Trial Testing the Effectiveness of Adaptive “SMART” Stepped-Care Treatment for Adults with Binge-Eating Disorder Co-morbid with Obesity. The American psychologist, 75(2), 204-218.
Publication 2019
Cholesterol Eating Disorders Genetic Heterogeneity Hypersensitivity neuro-oncological ventral antigen 2, human Orlistat Patient Dropouts Patients Pharmaceutical Preparations Physical Examination Placebos sibutramine Waist Circumference Weight-Loss Agents
5
Obesity and Depression Treatment Protocol
Cited 7 times
Women between the ages of 21 and 65 years old who meet criteria for obesity and MDD will be recruited. Table 1 summarizes the inclusion and exclusion criteria. Exclusion criteria were derived to: 1) minimize adverse effects of the intervention (e.g., physical limitations, does not receive physician clearance); 2) decrease error associated with the primary outcomes (e.g., taking weight loss medication or medications that influence weight); 3) prevent missing data (e.g., plans to move, no telephone) and 4) prevent participants who may require more intensive or more appropriate psychological intervention from enrolling in the study (e.g., active suicidal ideation, bipolar disorder, psychotic disorder). Participants who have been taking antidepressant medications (ADM) for more than 3 months and have no plans to change the regimen will be eligible. While participants who are on ADM will not be excluded, those in psychotherapy will be excluded because of potential conflicting therapeutic goals and possible contamination in the no therapy condition.
Schneider K.L., Bodenlos J.S., Ma Y., Olendzki B., Oleski J., Merriam P., Crawford S., Ockene I.S, & Pagoto S.L. (2008). Design and methods for a randomized clinical trial treating comorbid obesity and major depressive disorder. BMC Psychiatry, 8, 77.
Full text: Click here
Publication 2008
Antidepressive Agents Bipolar Disorder Infantile Neuroaxonal Dystrophy Obesity Pharmaceutical Preparations Physical Examination Physicians Psychotherapy Psychotic Disorders Therapeutics Treatment Protocols Weight-Loss Agents Woman

Most recents protocols related to «Weight-Loss Agents»

1
Lifestyle Intervention for Breast Cancer Risk
We included women previously identified according to NICE guidelines [8 ] as being at either moderate (≥17% to 29.99%) or high (>30%) lifetime risk of BC, aged ≥30 years with overweight or obesity (BMI ≥ 25 kg/m2). Previous personalised estimates of BC risk had been derived using the Tyrer-Cuzick model (version 8), which includes family history, hormonal risk factors, BMI+/− visually assessed mammographic density (Breast Imaging Reporting and Data System, BI-RADS) and a polygenic risk score (SNP 18) if these were available [16 ] in MFT and T&GICFT or had been based solely on family history information according to NICE CG164 guidance in UHS. Women were excluded if they did not have access to a phone or the internet, had a previous diagnosis of cancer, T2D or CVD, were currently prescribed statins, had a major physical or psychiatric condition which made them unsuitable for a home based diet and physical activity programme, were receiving weight loss medication (Orlistat), had previous bariatric surgery, or were already successfully following a diet and/or physical activity plan and had lost more than 1 kg of weight in the last 2 weeks. Only one woman per family was able to join the trial to avoid contamination between the groups.
Harvie M., French D.P., Pegington M., Lombardelli C., Krizak S., Sellers K., Barrett E., Gareth Evans D., Cutress R., Wilding RGN A., Graves L, & Howell A. (2023). Randomised controlled trial of breast cancer and multiple disease prevention weight loss programmes vs written advice amongst women attending a breast cancer family history clinic. British Journal of Cancer, 128(9), 1690-1700.
Full text: Click here
Publication 2023
Bariatric Surgery Breast Diagnosis Diet Hydroxymethylglutaryl-CoA Reductase Inhibitors Malignant Neoplasms Mental Disorders Obesity Orlistat Physical Examination RRAD protein, human Weight-Loss Agents Woman
2
Pooled VERTIS MET and ASIA Trial Analysis
This was a post hoc analysis of pooled data from two randomized, double-blind, placebo-controlled 26-week studies with similar overall designs and enrollment criteria: VERTIS MET (NCT02033889) [29 (link)] was conducted in 14 countries/regions that included Australia, South Africa, USA, Hong Kong, and Taiwan, and VERTIS ASIA (NCT02630706) [30 (link)] was conducted in five countries/regions (mainland China, Philippines, Hong Kong, Republic of Korea, and Taiwan). During VERTIS MET (n = 621) [29 (link)] and VERTIS ASIA (n = 506) [30 (link)], a total of 1127 participants were randomized across all sites. Both studies were conducted in compliance with the ethical principles of the Declaration of Helsinki and all International Conference on Harmonisation Good Clinical Practice Guidelines. For each study, informed consent was obtained from participants, and the final protocol and informed consent documentation were reviewed and approved by the institutional review board or independent ethics committee at each investigational center [29 (link), 30 (link)].
The study designs and eligibility criteria for VERTIS MET [29 (link)] and VERTIS ASIA [30 (link)] have been reported previously. Briefly, adults with T2D inadequately controlled with metformin monotherapy (HbA1c, 7.0–10.5% [53–91 mmol/mol] inclusive) were randomized to treatment with placebo, ertugliflozin 5 mg, or ertugliflozin 15 mg once daily for 26 weeks [29 (link), 30 (link)]. Key inclusion criteria were a minimum BMI of 18 kg/m2 in both studies, with a maximum of 40 kg/m2 for VERTIS MET and no upper limit in VERTIS ASIA [29 (link), 30 (link)]. Key exclusion criteria for both studies were body weight changes d≥ 5% in the previous 6 months associated with the use of a weight loss program, weight loss medication, or other medication associated with weight changes; and history of bariatric surgery.
In both studies, participants received glycemic rescue therapy (glimepiride) if they met (repeated and confirmed) prespecified FPG thresholds: > 270 mg/dL after randomization through week 6, > 240 mg/dL after week 6 through week 12, and > 200 mg/dL after week 12 through week 26. Counseling on appropriate dietary and lifestyle guidelines for T2D occurred at screening and participants were asked to maintain these guidelines throughout. Body weight was measured with a standardized digital scale, at approximately the same time of day after voiding, and the mean of duplicate readings used in the analysis. Sitting systolic blood pressure (SBP) was measured in triplicate with an automated oscillometric device. Laboratory analyses were performed at a central laboratory.
Ji L., Liu J., Xu Z.J., Wei Z., Zhang R., Malkani S., Cater N.B, & Frederich R. (2023). Efficacy and Safety of Ertugliflozin Added to Metformin: A Pooled Population from Asia with Type 2 Diabetes and Overweight or Obesity. Diabetes Therapy, 14(2), 319-334.
Publication 2023
Adult Bariatric Surgery Body Weight Conferences Diet Eligibility Determination ertugliflozin Ethics Committees Ethics Committees, Research glimepiride Inclusion Bodies Medical Devices Metformin Oscillometry Pharmaceutical Preparations Placebos Systolic Pressure Therapeutics Weight-Loss Agents Weight Reduction Programs
3
Perioperative Glucose Dynamics in Spine Surgery
We conducted an observational study of patients undergoing multi‐level spine surgery with the approval of the University of Vermont Institutional Review Board (M14‐291; NCT04396964). All subjects gave written informed consent prior to participation. Subjects were eligible if they were >18 years old without acute or chronic health conditions including cardiac, pulmonary, hepatic, renal, auto‐immune, or hematological disease. Obese subjects with body mass index >40 kg/m2 were excluded. Subjects with Type 2 diabetes were eligible if they were well‐controlled (HbA1c < 7.5%) and treated with diet and exercise, metformin, or insulin. Subjects were excluded if taking other hypoglycemic agents, weight loss medication, or other medications affecting glucose homeostasis. Enrollment lasted from 2014–2016.
Subjects presented to preoperative hold after an overnight fast and had a dedicated peripheral intravenous line placed for blood sampling. No medications were administered through this line. Baseline samples were collected in preoperative hold and after transfer to the operating room. After the blood sampling in preoperative hold, patients received any medications associated with an enhanced recovery pathway. Following induction and intubation blood samples were collected at 15′ intervals for the initial 2 h of each case, then at 30′ intervals for the remainder of the case until emergence and extubation. A blood sample was collected on arrival to the post‐anesthesia care unit and again 1 h later (Figure 1). Blood samples were collected on ice and aliquoted into potassium oxalate, potassium EDTA, and serum‐separating tubes. Samples were processed immediately and stored at −80°C until analyzed. Demographic and anthropomorphic data were collected from the medical record. Intraoperative data were collected from the anesthesia record. Hemodynamic data were aligned to the time of intubation and underwent a 5‐min average smoothing.
Tharp W.G., Breidenstein M.W., Friend A.F., Bender S.P, & Raftery D. (2023). The neuroendocrine stress response compensates for suppression of insulin secretion by volatile anesthetic agents: An observational study. Physiological Reports, 11(4), e15603.
Full text: Click here
Publication 2023
Anesthesia BLOOD Chronic Condition Diabetes Mellitus, Non-Insulin-Dependent Diet Edetic Acid, Potassium Salt Ethics Committees, Research Glucose Heart Hematological Disease Hemodynamics Homeostasis Hypoglycemic Agents Index, Body Mass Insulin Intubation Kidney Lung Metformin Obesity Operative Surgical Procedures Patients Pharmaceutical Preparations Potassium Oxalate Serum Tracheal Extubation Vertebral Column Weight-Loss Agents
4
Improving Sexual Function in Obese Women
All participants were selected as obese, non-smoking, married women having sexual dysfunction (FSFI’s score < 28.1) and seeking weight loss programs for cosmetic purposes only. Their ages ranged from 20 to 40 years with a BMI of 30 kg/m2 or above, and a parity number ranged from 1 to 3 times. The exclusion criteria were polycystic ovarian disease, any gynecological disease, fibroids, pelvic surgery or radiotherapy, anemia, diabetes, hypertension, cardiovascular disease, thyroid disease, neurological disorder, rheumatoid arthritis, bariatric surgery, or taking weight loss medication. Also, women who had not engaged in sexual activity in the previous 6 months, as well as those who were pregnant or breastfeeding, were excluded from the study.
Abdelsamea G.A., Amr M., Tolba A.M., Elboraie H.O., Soliman A., Al-Amir Hassan B., Ali F, & Osman D.A. (2023). Impact of weight loss on sexual and psychological functions and quality of life in females with sexual dysfunction: A forgotten avenue. Frontiers in Psychology, 14, 1090256.
Full text: Click here
Publication 2023
Anemia Bariatric Surgery Cardiovascular Diseases Diabetes Mellitus Female Genital Diseases High Blood Pressures Nervous System Disorder Obesity Operative Surgical Procedures Pelvis Polycystic Ovary Syndrome Radiotherapy Rheumatoid Arthritis Thyroid Diseases Uterine Fibroids Weight-Loss Agents Weight Reduction Programs Woman
5
Metabolic Profiles in Obesity and Diabetes
The study population included a total of 60 participants, 20 participants of whom were healthy and non-obese, 20 obese (BMI > 30 kg/m2) and 20 who had been diagnosed with type 2 diabetes. Participants were identified via Primary Care, Diabetes Outpatient Clinics, the Graz Diabetes Registry for Biomarker Research (GIRO) and adverts. Participants in the healthy non-obese cohort were included if they were 18 years and older, had a body mass index (BMI) between 20.0 and 27.0 kg/m2 and a fasting plasma glucose level lower than 110 mg/dL (without medication). Participants of the obese cohort had to have a BMI > 30.0 kg/m2 and a fasting plasma glucose level < 110 mg/dL (without medication). Individuals were excluded from both these cohorts if they had a history of type 1 or type 2 diabetes or established cardiovascular disease, were taking weight loss medications, were heavily drinking (more than 15 alcoholic drinks/week), or were taking any glucose lowering, lipid lowering or antihypertensive medication. Additionally, pregnant, or breast-feeding women and individuals on corticosteroids or antidepressants within 6 months prior to study initiation were excluded.
Patients in the third cohort were required to have established type 2 diabetes on either diet or a monotherapy or combination therapy of oral glucose lowering drugs [12 (link)]. The trial was approved by the Ethics Committee of the Medical University of Graz (30–238 ex 17/18) and was conducted at the Interdisciplinary Metabolic Medicine Trials Unit, Division of Endocrinology and Diabetology at the Medical University of Graz, Austria. All participants provided written informed consent before enrolling in the study.
Tripolt N.J., Hofer S.J., Pferschy P.N., Aziz F., Durand S., Aprahamian F., Nirmalathasan N., Waltenstorfer M., Eisenberg T., Obermayer A.M., Riedl R., Kojzar H., Moser O., Sourij C., Bugger H., Oulhaj A., Pieber T.R., Zanker M., Kroemer G., Madeo F, & Sourij H. (2023). Glucose Metabolism and Metabolomic Changes in Response to Prolonged Fasting in Individuals with Obesity, Type 2 Diabetes and Non-Obese People—A Cohort Trial. Nutrients, 15(3), 511.
Full text: Click here
Publication 2023
Adrenal Cortex Hormones Alcoholic Beverages Antidepressive Agents Antihypertensive Agents Biological Markers Cardiovascular Diseases Combination Drug Therapy Diabetes Mellitus Diabetes Mellitus, Non-Insulin-Dependent Diet Ethics Committees Glucose Healthy Volunteers Index, Body Mass Lipids Obesity Patients Pharmaceutical Preparations Plasma Primary Health Care System, Endocrine Weight-Loss Agents Woman

Top products related to «Weight-Loss Agents»

1
Spss version 23 by IBM
Sourced in United States, United Kingdom, Japan, Austria, Germany, Belgium, Israel, Hong Kong, India
SPSS version 23 is a statistical software package developed by IBM. It provides tools for data analysis, data management, and data visualization. The core function of SPSS is to assist users in analyzing and interpreting data through various statistical techniques.
2
449 f3 jupiter by Netzsch
Sourced in Germany
The 449 F3 Jupiter is a thermal analysis instrument designed for thermogravimetric analysis (TGA). It measures the change in mass of a sample as a function of temperature or time under a controlled atmosphere. The instrument can be used to analyze a wide range of materials, including polymers, ceramics, and metals.

More about "Weight-Loss Agents"

Explore the fascinating world of weight-loss agents - substances, supplements, and lifestyle modifications designed to facilitate healthy weight reduction.
These cutting-edge interventions, studied by researchers, aim to unlock the secrets of safe and effective weight management.
From pharmacological agents to dietary supplements, the latest innovations in this field can empower individuals to achieve their goals.
Uncover the latest breakthroughs in weight-loss agent optimization through publications, preprints, and patents.
Harness the power of AI-driven research tools like PubCompare.ai to effortlessly locate and compare the most promising protocols, giving you a decisive edge in your work.
Delve into the nuances of SPSS version 23 and the 449 F3 Jupiter model to gain a deeper understanding of the factors that influence weight-loss agent efficacy.
Whether you're a researcher, healthcare professional, or individual seeking to optimize your weight-loss journey, this comprehensive overview of weight-loss agents, their related terms, and the latest research insights will prove invaluable.
Embrace the power of innovation and unlock your full potential in the dynamic field of weight management.